Fiche traitement
Methotrexate
WEI XU • Cancer
Suivi actif
Non applicable
Résumé
Methotrexate est développé par WEI XU. Le traitement est actuellement en Non applicable. Il est associé à Cancer. Son objectif thérapeutique principal est Ralentissement de la progression. Le statut actuel est : suivi actif.
À vérifier
Ralentissement de la progression
Non applicable
WEI XU
China
This phase II/III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone.
2026-08-12
Début phase actuelle
Non disponible dans les sources synchronisées
Timeline clinique
Non applicable
Début phase actuelle
Non disponible dans les sources synchronisées
Préclinique
Phase 1
Phase 2
Phase 3
Approuvé
Objectif scientifique de l’étude
classification automatique vérifiable
Ralentissement de la progression
Confiance automatique : 66%
Ce pourcentage n’est pas une probabilité de succès clinique.
Il mesure uniquement la force de la classification automatique de l’objectif scientifique. Le calcul part de 45 points, ajoute 7 points par unité de poids du mot-clé le plus fortement détecté, puis est plafonné à 95 %. Exemple : un score maximal de 2 donne 45 + (2 × 7) = 59 %.
Indices détectés : progression → Ralentissement de la progression, immune → Immunomodulation
Ce score est heuristique et doit être vérifié dans le protocole ou une publication.
Description affichée depuis l’essai compatible NCT04628767, afin d’éviter le mélange entre plusieurs indications d’une même molécule.
Aucune incohérence majeure détectée entre la maladie, l’objectif et la description.
Transparence et qualité de la fiche
données vérifiablesClassificationCohérente automatiquement
Confiance de la fiche100 %
Source principaleSource officielle ou publication indexée
Dernière vérification2026-08-12
Anomalies détectées0
Validation humaineValidation humaine non effectuée
Donnée issue d’une source
Donnée normalisée automatiquement
Interprétation algorithmique
Classification scientifique multi-axes
ne pas confondre statut et résultatÉtat de l’étudeRecrutement en cours
Disponibilité des résultatsRésultats à vérifier
InterprétationImpossible à déterminer
Niveau de preuveNon évaluable
Un essai terminé n’est pas nécessairement positif. Un essai arrêté n’est classé comme échec scientifique que lorsqu’un résultat ou une raison explicite le confirme.
Indicateurs factuels
sans score subjectifPhase enregistréeNon applicable
Études associées5
Publications associées23
Statut consolidéSuivi actif
Aucune chance de succès, note d’innovation, potentiel thérapeutique ou probabilité de commercialisation n’est calculé tant qu’un modèle validé et des données suffisantes ne sont pas disponibles.
Historique factuel de la molécule
40 événement(s) daté(s)Cette liste reprend uniquement les dates trouvées dans les registres et publications liés. Elle ne constitue pas une prévision.
| Date | Événement | Source |
|---|---|---|
| 2008-10-01 | Début de l’étudeNCT00727194 | Registre d’essai clinique |
| 2011-07-01 | Fin de l’étude prévue / enregistréeNCT00727194 | Registre d’essai clinique |
| 2021-11-12 | Début de l’étudeNCT04628767 | Registre d’essai clinique |
| 2023-03-03 | Début de l’étudeNCT05691478 | Registre d’essai clinique |
| 2026-07-08 | Création de l’enregistrementNCT00727194 | Registre d’essai clinique |
| 2026-07-10 | PublicationRefractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. | Cureus |
| 2026-07-13 | Dernière mise à jour du registreNCT00727194 | Registre d’essai clinique |
| 2026-07-14 | PublicationBreakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology |
| 2026-07-15 | PublicationDrug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis using FAERS. | European journal of pediatrics |
| 2026-07-18 | PublicationFacial solitary morphea profunda presenting with painful trigeminal neuropathy: A case report. | Cephalalgia : an international journal of headache |
| 2026-07-22 | PublicationCase Report: Severe ANCA-positive eosinophilic granulomatosis with polyangiitis presenting with Loeffler endocarditis and cryofibrinogenemia-associated digital gangrene successfully treated with rituximab. | Frontiers in immunology |
| 2026-07-23 | Publication[Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia]. | La Revue de medecine interne |
| 2026-07-23 | Publication[Sarcoidosis-associated uveitis: Current status and future prospects]. | La Revue de medecine interne |
| 2026-08-01 | Début de l’étudeNCT07764601 | Registre d’essai clinique |
| 2026-08-11 | Début de l’étudeNCT07678229 | Registre d’essai clinique |
| 2026-08-12 | Dernière mise à jour des donnéesMethotrexate | Biomedical Watch |
| 2026-08-13 | Création de l’enregistrementNCT07678229 | Registre d’essai clinique |
| 2026-08-13 | PublicationElderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options. | Medicina (Kaunas, Lithuania) |
| 2026-08-13 | PublicationEvolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review. | Cureus |
| 2026-08-13 | PublicationCase Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases. | Frontiers in pediatrics |
| 2026-08-13 | PublicationThe Liver-Heart Axis in Rheumatoid Arthritis: Associations of Liver Fibrosis, Organokines, Endothelin-1, and Cardiovascular Risk. | International journal of molecular sciences |
| 2026-08-13 | PublicationLeucovorin Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. | Anticancer research |
| 2026-08-16 | Création de l’enregistrementNCT07764601 | Registre d’essai clinique |
| 2026-08-16 | Création de l’enregistrementNCT05691478 | Registre d’essai clinique |
| 2026-08-16 | PublicationHigh-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. | Lancet (London, England) |
| 2026-08-16 | PublicationLong-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial. | The Lancet. Rheumatology |
| 2026-08-16 | PublicationLiposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance. | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy |
| 2026-08-16 | PublicationReduced-Dose PTCy Plus Post-Engraftment Low-Dose ATG for GVHD Prophylaxis in Haploidentical PBSC Transplantation. | Transplantation and cellular therapy |
| 2026-08-16 | PublicationVitreoretinal Lymphoma: A Comprehensive Clinical Review and Current Standards in Management. | Journal of vitreoretinal diseases |
| 2026-08-16 | PublicationEffectiveness of oral cryotherapy in preventing methotrexate-induced oral mucositis in pediatric patients with acute lymphoblastic leukemia: a randomized controlled trial. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer |
| 2026-08-16 | PublicationVitreoretinal lymphoma revealing Richter transformation. | American journal of ophthalmology case reports |
| 2026-08-16 | PublicationHopeFOL, or FOL of problems? Leucovorin for autistic symptoms. | The oncologist |
| 2026-08-16 | PublicationExploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy. | Gut microbes |
| 2026-08-16 | PublicationLiposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma. | Drug delivery |
| 2026-09-01 | PublicationZilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy. | JAMA dermatology |
| 2026-09-03 | Création de l’enregistrementNCT04628767 | Registre d’essai clinique |
| 2027-09-30 | Fin de l’étude prévue / enregistréeNCT04628767 | Registre d’essai clinique |
| 2029-08-01 | Fin de l’étude prévue / enregistréeNCT07764601 | Registre d’essai clinique |
| 2030-03-20 | Fin de l’étude prévue / enregistréeNCT05691478 | Registre d’essai clinique |
| 2031-12-31 | Fin de l’étude prévue / enregistréeNCT07678229 | Registre d’essai clinique |
Début phase actuelle
Non disponible dans les sources synchronisées
Essais cliniques liés
5 essai(s)
Début phase actuelle
Non disponible dans les sources synchronisées
| NCT | Titre | Phase | Statut administratif | Pays | Sponsor |
|---|---|---|---|---|---|
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | RECRUITING | United States | National Cancer Institute (NCI) |
| NCT07764601 | RM-MA-PD1 — R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma | Non applicable | NOT_YET_RECRUITING | China | WEI XU |
| NCT05691478 | A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | SUSPENDED | United States, Australia, Canada, New Zealand | National Cancer Institute (NCI) |
| NCT07678229 | BRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL | Phase 3 | RECRUITING | China | Rong Tao |
| NCT00727194 | Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis | Phase 2 | TERMINATED | United States, Canada, United Kingdom | Alexion Pharmaceuticals, Inc. |
Publications liées
23 publication(s)Publications liées
23 publication(s)| Titre | PMID | DOI | Journal | Date |
|---|---|---|---|---|
| Zilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy. Voir source | 42616491 | 10.1001/jamadermatol.2026.2314 | JAMA dermatology | |
| High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. Voir source | 42486133 | 10.1016/S0140-6736(26)00917-7 | Lancet (London, England) | |
| Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial. Voir source | 42392130 | 10.1016/S2665-9913(26)00109-8 | The Lancet. Rheumatology | |
| Liposomes containing histidine overcome poly ADP-ribose polymerase inhibitor resistance. Voir source | 42287952 | 10.1016/j.drup.2026.101432 | Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy | |
| Reduced-Dose PTCy Plus Post-Engraftment Low-Dose ATG for GVHD Prophylaxis in Haploidentical PBSC Transplantation. Voir source | 42532275 | 10.1016/j.jtct.2026.07.033 | Transplantation and cellular therapy | |
| Vitreoretinal Lymphoma: A Comprehensive Clinical Review and Current Standards in Management. Voir source | 42602195 | 10.1177/24741264261474159 | Journal of vitreoretinal diseases | |
| Effectiveness of oral cryotherapy in preventing methotrexate-induced oral mucositis in pediatric patients with acute lymphoblastic leukemia: a randomized controlled trial. Voir source | 42599331 | 10.1007/s00520-026-11075-1 | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer | |
| Vitreoretinal lymphoma revealing Richter transformation. Voir source | 42564912 | 10.1016/j.ajoc.2026.102631 | American journal of ophthalmology case reports | |
| HopeFOL, or FOL of problems? Leucovorin for autistic symptoms. Voir source | 42536436 | 10.1093/oncolo/oyag304 | The oncologist | |
| Exploring the gut microbiome and metabolomic interactions of antimetabolite drugs to optimize therapy. Voir source | 41758194 | 10.1080/19490976.2026.2638009 | Gut microbes | |
| Liposome-mediated delivery of a ruthenium-based metallodrug to overcome cisplatin resistance in osteosarcoma. Voir source | 42116576 | 10.1080/10717544.2026.2671485 | Drug delivery | |
| Elderly-Onset Rheumatoid Arthritis: Characteristics and Treatment Options. Voir source | 37893596 | 10.3390/medicina59101878 | Medicina (Kaunas, Lithuania) | |
| Evolving Treatment Strategies for Systemic Lupus Erythematosus in Clinical Practice: A Narrative Review. Voir source | 39759646 | 10.7759/cureus.75062 | Cureus | |
| Case Report: Telitacicept in the treatment of refractory juvenile idiopathic arthritis: clinical experience from three cases. Voir source | 42582370 | 10.3389/fped.2026.1846557 | Frontiers in pediatrics | |
| The Liver-Heart Axis in Rheumatoid Arthritis: Associations of Liver Fibrosis, Organokines, Endothelin-1, and Cardiovascular Risk. Voir source | 42589498 | 10.3390/ijms27156844 | International journal of molecular sciences | |
| Leucovorin Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. Voir source | 42527076 | 10.21873/anticanres.18311 | Anticancer research | |
| [Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia]. Voir source | 42486736 | 10.1016/j.revmed.2026.07.001 | La Revue de medecine interne | |
| [Sarcoidosis-associated uveitis: Current status and future prospects]. Voir source | 42486737 | 10.1016/j.revmed.2026.05.006 | La Revue de medecine interne | |
| Case Report: Severe ANCA-positive eosinophilic granulomatosis with polyangiitis presenting with Loeffler endocarditis and cryofibrinogenemia-associated digital gangrene successfully treated with rituximab. Voir source | 42483201 | 10.3389/fimmu.2026.1882906 | Frontiers in immunology | |
| Facial solitary morphea profunda presenting with painful trigeminal neuropathy: A case report. Voir source | 30213201 | 10.1177/0333102418801580 | Cephalalgia : an international journal of headache | |
| Drug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis using FAERS. Voir source | 42448984 | 10.1007/s00431-026-07251-4 | European journal of pediatrics | |
| Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. Voir source | 42444056 | 10.1111/pai.70425 | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology | |
| Refractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. Voir source | 42422651 | 10.7759/cureus.110468 | Cureus |
Sources officielles
liens de rechercheDernière mise à jour des données : 2026-08-12
Ces sources sont proposées pour vérification. Les informations de la fiche doivent être confirmées dans les registres officiels ou les publications originales.